[1] Stabenow R, Eisinger B (2001): Epidemiologische Daten zum weiblichen Brustkrebs aus dem Gemeinsamen Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt und der Freistaaten Sachsen und Thüringen. Schriftenreihe des GKR 1/ 2001: 40

[2]Jemal A, Thomas A, Murray T, Thun M (2002): Cancer Statistics, 2002. CA Cancer J Clin 52: 23-47

[3]Kreienberg R, Volm T, Alt D (2002): Krankheitsbild: Mammakarzinom. In: Kreienberg R, Volm T, Möbus V, Alt D (Hrsg.): Management des Mammakarzinoms. 2. Auflage. Springer- Verlag, Berlin Heidelberg New York, 3-6

[4]Riede UN, Wittekind C, Sterry W (1999): Epidermodermales System. In: Riede UN, Schaefer HE (Hrsg.): Allgemeine und spezielle Pathologie. 4. Auflage. Thieme . Stuttgart New York , 954-961

[5]Arun B, Hortobagyi GN (2002): Progress in breast cancer chemoprevention. Endocr Relat Cancer 9: 15-32

[6]Preiß J, Dornoff W, Hagmann FG, Schmieder A (2002): Onkologie 2002/ 2003, Empfehlungen zur Therapie. 11. Auflage . W. Zuckerschwerdt Verlag GmbH, 127-146

[7]Balkwill F, Mantovani A (2001): Inflammation and cancer: back to Virchow?. Lancet 357: 539-545

[8]Dvorak HF (1986): Tumors: wounds that do not heal. N Engl J Med 315: 1650-1659

[9]Hauptmann S (2000): Die Rolle der Entzündung bei der Tumorinvasion. Verh. Dtsch. Ges. Path. 84: 77-86

[Seite 72↓]

[10]Vane JR (1971): Inhibition of prostaglandin synthesis as a mechanism of action for Aspirin-like drugs. Nat New Biol 231: 232-235

[11]Vane JR, Flower RJ, Botting RM (1990): History of Aspirin and its mechanism of action. Stroke 21 (4): IV12-23

[12]Taketo MM (1998): Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst. 90 (20): 1529-1536

[13]Stack E, DuBois RN (2001): Regulation of cyclo-oxygenase-2. Best Pract Res Clin Gastroenterol 15 (5): 787-800

[14]Hla T, Bishop- Bailey D, Liu CH, Schaefers HJ, Trifan OC (1999): Cyclooxygenase-1 and –2 isoenzymes. Int J Biochem Cell Biol 31 : 551-557

[15]Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ (2001): Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8: 97-114

[16]Taketo MM (1998): Cyclooygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst. 90 (21): 1609-1620

[17]Cannon GW, Breedveld FC (2001): Efficacy of Cyclooxygenase- 2- specific inhibitors. Am J Med 110 (3A): 6S-12S

[18]Brune K, Kalden J, Zacher J, Zeilhofer HU (2000): Selektive Inhibitoren der Zykooxygenase 2. Deutsches Ärzteblatt 97 (26): A-1818-A1825

[19]Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su L-K, Sherman J, Kelloff G, Levin B, Steinbach G, the FAP Study Group (2002): A randomised, double blind, placebo controled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 50 (6): 857-860

[20]Khuder SA, Mutgi AB (2001): Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84 (9): 1188-1192

[Seite 73↓]

[21]Johnson TW, Anderson KE, Lazovich DA, Folsom AR (2002): Association of Aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 11: 1586-1591

[22]Elston CW, Ellis IO (1991): Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 5: 403-410

[23]Sobin LJ, Wittekind L (2002): TNM classification of malignant tumors. Wiley-Liss, 6. ed.

[24]Remmele W, Stegner HE (1987): Recommendation for uniform definition of an immunoreactive score (IRS) for immunhistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140

[25]Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002): Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681

[26]Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002): Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer . Cancer Res 62 : 632-635

[27]Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF (2001): Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 61: 4375-4381

[28]Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N (2000): Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients . Clin. Cancer Res 6: 4064-4068

[29]Newton R, Kuitert LME, Bergmann M, Adcock IM, Barnes PJ (1997): Evidence for involvement of NF- κ B in the transcriptional control of COX-2 gene expression by IL-1 β . Biochem Biophys Res Commun (237): 28-32

[Seite 74↓]

[30]Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S. (2003): Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survivall and overall survivall in patients with breast carcinoma. Cancer 97 (12): 2978-2987

[31]Soslow RA, Dannenberg AJ, Rudh D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000): COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (12): 2637-2645

[32]Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC (2002): Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55: 429-434

[33]Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R, Obrist P (2003): Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer (88): 574-578

[34]Davies G, Salter J, Hills M, Martin L-A, Sacks N, Dowsett M (2003): Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin. Cancer Res 9: 2651-2656

[35]Lim SC (2003) : Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. Oncol Rep. 10 (5): 1241-1249

[36]Wülfing P, Diallo R, Müller C, Wülfing C, Poremba C, Heinecke A, Rody A, Greb RR, Böcker W, Kiesel L (2003): Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129: 375-382

[37]Denkert C, Köbel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S (2002): Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160: 893-903

[Seite 75↓]

[38]Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N (2000): Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6 (10): 4064-4068

[39]Shono T, Tofilon PJ, Brunner JM, Owolabi O, Lang FF (2001): Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 61: 4375-4381

[40]Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000): The cyclooxygenase-2 inhibitor Celecoxib is a potent preventive and therapeutic agent in the Min Mouse Model of adenomatous polyposis. Cancer Res (60): 5040-5044

[41]Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000): Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101-2103

[42]Liu XH, Rose DP (1996): Differential expression and regulation of cyclooygenase-1 and –2 in two human breast cancer cell lines. Cancer Res 56: 5152-5127

[43]Parente L, Perretti M (2003): Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 65: 153-159

[44]Huang M, Sharma S, Mao JT, Dubinett SM (1996): Non-small lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 157 (12): 5512-5520

[45]Tsujii M, DuBois RN (1995): Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (3): 493-501

[Seite 76↓]

[46]DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD (1996): G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 56 (4): 733-737

[47]Tsujii M, Kawano S, DuBois RN (1997): Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340

[48]Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, Inoue H, Tanabe T, Yoshimoto T (1999): Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or –2. FEBS Lett 460 (1): 145-148

[49]Lim SC, Park SY, Do NY (2003): Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. Oncol Rep. 10 (5): 1073-1079

[50]Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT (2003): Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther (1): 1-7

[51]Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998): Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 94 (2): following 271

[52]Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000): Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105: 1589-1594

[53]Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ (1999): Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis . Cancer Res 59: 4574-4577

[54]Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawaski AS (1999): Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 12 (5): 1418-1423

[Seite 77↓]

[55]Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998): Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58 (2): 362-366

[56]Rigas B, Shiff SJ (2000): Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction . Med Hypotheses 54 (2): 210-221

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: